1-11 of 11
Pratik S. Multani
Close
Sort by
Journal Articles

Preliminary Results of the Oral CD73 Inhibitor, Oric-533, in Relapsed/Refractory Multiple Myeloma (RRMM)

Cesar Rodriguez, Scott R. Solomon, Barry Paul, Omar Nadeem, Meenal Patel, Jian Wang, Rongda Xu, Melissa Junttila, Anneleen Daemen, Subhash Katewa, Pratik S Multani, Wilson I. Gonsalves
Journal: Blood
Blood (2023) 142 (Supplement 1): 4761.
https://doi.org/10.1182/blood-2023-173730
Published: 2023
Journal Articles

CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma

Melissa R Junttila, Arghya Ray, Robert Warne, Xi R Chen, Ting Du, Fang Lui, Subhash Katewa, Brian Blank, Jared Moore, Chudi Ndubaku, Christophe Colas, Pratik S Multani, Omar Nadeem, Dharminder Chauhan, Kenneth C. Anderson, Lori Friedman
Journal: Blood
Blood (2022) 140 (Supplement 1): 9957–9958.
https://doi.org/10.1182/blood-2022-168275
Published: 2022
Journal Articles

Ex Vivo Pharmacologic Modulation in a Nutrient-Rich Medium to Accelerate Engraftment of Human Umbilical Cord Blood

Corey S Cutler, MD MPH, Daniel Shoemaker, PhD, Peter Westervelt, MD PhD, Daniel R. Couriel, MD, Sumithra Vasu, MBBS, Luis M. Isola, MD, Chatchada Karanes, MD, Laura Newell, MD, Betsy Rezner, BS, Lisa Guerrettaz, PhD, David Robbins, BS, Amanda Medcalf, BS, MT(ASCP), Scott Wolchko, MS, John Ferraro, MBA, Pratik S. Multani, MD MS
Journal: Blood
Blood (2014) 124 (21): 3807.
https://doi.org/10.1182/blood.V124.21.3807.3807
Published: 2014
Journal Articles

Ex Vivo Modulation of Mobilized Peripheral Blood: Characterization of HSC and T-Cell Responses to Prostaglandin E2

David Robbins, BS, Thuy Le, BS, Christopher Troung, BS, Heather Foster, BS, Betsy Rezner, BS, Leah Mitchell, PhD, Lisa Guerrettaz, PhD, Pratik S. Multani, MD MS, Daniel Shoemaker, PhD
Journal: Blood
Blood (2014) 124 (21): 1092.
https://doi.org/10.1182/blood.V124.21.1092.1092
Published: 2014
Journal Articles

FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation

Corey S. Cutler, MD, MPH, FRCPC, Daniel Shoemaker, PhD, Karen K. Ballen, MD, David Robbins, Caroline Desponts, PhD, Grace S. Kao, MD, Yi-Bin A. Chen, MD, Bimalangshu R. Dey, MD, Steven L. McAfee, MD, Edwin P Alyea, III, MD, John Koreth, MBBS, DPhil, Philippe Armand, MD, PhD, Vincent T Ho, MD, Haesook T Kim, PhD, Wolfram Goessling, MD, PhD, Trista E. North, Ph.D., Thomas R. Spitzer, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Jerome Ritz, MD, John Mendlein, PhD, Pratik S. Multani, MD, MS
Journal: Blood
Blood (2011) 118 (21): 653.
https://doi.org/10.1182/blood.V118.21.653.653
Published: 2011
Journal Articles

Use of Genome-Wide Expression Analysis to Optimize An Ex Vivo clinical Protocol for 16,16-Dimethyl Prostaglandin E2 Enhancement of Umbilical Cord Blood In Hematopoietic Stem Cell Transplantation.

Caroline Desponts, PhD, David Robbins, Thuy Le, Annie Chi, Scott Thies, PhD, Myriam Armant, PhD, Corey Cutler, MD, MPH, FRCPC, John Mendlein, PhD, Paul Grayson, Pratik S. Multani, MD, MS, Daniel Shoemaker, PhD
Journal: Blood
Blood (2010) 116 (21): 1451.
https://doi.org/10.1182/blood.V116.21.1451.1451
Published: 2010
Journal Articles

Phase I/II Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Pgp-Positive Acute Myeloid Leukemia (AML).

Jeffrey E. Lancet, MD, Jason Gotlib, MD, Meir Wetzler, MD, Selina Luger, MD, Larry D. Cripe, MD, Martin S. Tallman, MD, Ivana Gojo, MD, Deborah Mulford, MD, Maria R. Baer, MD, Alan F. List, MD, Pratik S. Multani, MD, Branimir I. Sikic, MD
Journal: Blood
Blood (2007) 110 (11): 299.
https://doi.org/10.1182/blood.V110.11.299.299
Published: 2007
Journal Articles

Phase I/II Pharmacodynamic Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Acute Myeloid Leukemia (AML).

Jeffrey Lancet, Maria R. Baer, Larry D. Cripe, Alan F. List, John F. Marcelletti, Pratik S. Multani, Branimir I. Sikic
Journal: Blood
Blood (2006) 108 (11): 422.
https://doi.org/10.1182/blood.V108.11.422.422
Published: 2006
Journal Articles

SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL).

Jonathan Friedberg, MD, Philip Cohen, MD, Robert O. Kerr, MD, K. Sue Robinson, MD, Andres Forero-Torres, MD, Richard van der Jagt, MD, Elber Camacho, MD, John Hainsworth, MD, Brent Roeck, Pratik S. Multani, MD
Journal: Blood
Blood (2004) 104 (11): 2480.
https://doi.org/10.1182/blood.V104.11.2480.2480
Published: 2004
Journal Articles

No clinical evidence for CD4 + cell depletion caused by rituximab

M. Wayne Saville, Mark C. Benyunes, Pratik S. Multani
Journal: Blood
Blood (2003) 102 (1): 408–409.
https://doi.org/10.1182/blood-2003-03-1005
Published: 2003
Journal Articles

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Clinical Trials & Observations
Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani, Thomas E. Witzig, Stewart Spies, Nancy L. Bartlett, Russell J. Schilder, James L. Murray, Mansoor Saleh, Roberta S. Allen, Antonio J. Grillo-López, Christine A. White
Journal: Blood
Blood (2002) 99 (12): 4336–4342.
https://doi.org/10.1182/blood.V99.12.4336
Published: 2002